Cyclacel Pharmaceuticals (STU:UXI) Other Net Income (Loss) : €-0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Cyclacel Pharmaceuticals Other Net Income (Loss)?

Cyclacel Pharmaceuticals's Other Net Income (Loss) for the three months ended in Mar. 2024 was €0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.00 Mil.

Cyclacel Pharmaceuticals's quarterly Other Net Income (Loss) declined from Sep. 2023 (€-0.00 Mil) to Dec. 2023 (€-0.00 Mil) but then increased from Dec. 2023 (€-0.00 Mil) to Mar. 2024 (€0.00 Mil).

Cyclacel Pharmaceuticals's annual Other Net Income (Loss) declined from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.00 Mil) but then stayed the same from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

Cyclacel Pharmaceuticals Other Net Income (Loss) Historical Data

The historical data trend for Cyclacel Pharmaceuticals's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclacel Pharmaceuticals Other Net Income (Loss) Chart

Cyclacel Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

Cyclacel Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Cyclacel Pharmaceuticals Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.00 Mil.

Cyclacel Pharmaceuticals Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclacel Pharmaceuticals (STU:UXI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (STU:UXI) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

CYCCP.PFD:USA CYCC:USA

Address

200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922

Website

https://www.cyclacel.com

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

Cyclacel Pharmaceuticals (STU:UXI) Headlines

No Headlines